A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas

Trial Profile

A Phase 2 Study of Brentuximab Vedotin Plus Cyclophosphamide, Doxorubicin, Etoposide, and Prednisone (CHEP-BV) Followed by BV Consolidation in Patients With CD30-Positive Peripheral T-Cell Lymphomas

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2017

At a glance

  • Drugs Brentuximab vedotin (Primary) ; Cyclophosphamide; Doxorubicin; Etoposide; Prednisone
  • Indications Anaplastic large cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T cell lymphoma; T-cell leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jun 2017 According to a Seattle Genetics media release, based on the data from a phase III ALCANZA study and two phase 2 investigator-sponsored trials in patients with cutaneous T-cell lymphoma the company has submitted a supplemental Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA).
    • 26 May 2017 Planned End Date changed from 1 Jun 2019 to 1 May 2019.
    • 26 May 2017 Planned primary completion date changed from 1 Jun 2019 to 1 May 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top